Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

To be considered for this study, you would generally need to be between 50 and 85 years old. You should have received a diagnosis of early Alzheimer's disease or be experiencing mild to moderate symptoms that are consistent with Alzheimer's. An important requirement is that a brain scan (called an amyloid PET scan) must show evidence of 'amyloid' in your brain, which is a protein linked to Alzheimer's.

You would also need to be able to understand and sign consent forms yourself. Crucially, you'd need a 'study partner' – someone who knows you well, can be in regular contact with you, and can commit to helping you throughout the study. This partner would also need to agree to take part. You should be willing to undergo various tests, including brain scans, blood tests, and a spinal tap (lumbar puncture).

There are also some other criteria, such as having a good enough memory and thinking ability to complete study assessments (even with assistance) and being able to see and hear well enough for certain tests. You also couldn't be involved in other research studies at the same time or donate blood for a period after the study.

If you decide to participate, you will receive either the study drug RO7126209 or a placebo (an inactive substance designed to look like the drug) through an intravenous drip. You won't know which one you are receiving. The study involves regular visits to the clinic, where you will undergo various assessments. These include memory and thinking tests, magnetic resonance imaging (MRI) scans of your brain, and positron emission tomography (PET) scans to look at your brain for specific proteins related to Alzheimer's disease. You will also have blood tests and a lumbar puncture (spinal tap) to collect fluid from around your spinal cord.

Throughout the study, your health will be closely monitored, and you will have check-ups to assess your safety and how you are tolerating the treatment. You'll need to have a trusted 'study partner' who can come to appointments with you, help with assessments, and provide information about your daily life. The exact number of visits and the total duration of your participation will be explained in detail by the study team.